Cardiology

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

A look at how European experts have shaped risk assessment through demographic-centric algorithms.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

An expert weighs in on improving guidelines to reflect optimal real-world care for patients at high risk of cardiovascular events.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

Announced in a statement on September 1, the FDA warning is an update to the FDA Drug Safety Communication issued on February 4, 2021 and the results of a review of a trial that found a serious increased risk of CV-related events with the drug.

Our latest cardiology case report from Brady Pregerson, MD, features an elderly man brought to the emergency department as a code STEMI from home for altered mental status and shortness of breath. Can you determine the correct diagnosis?

Overall positive genetic test results for variants was 10.1% for patients diagnosed with AF before 66 years of age and 16.8% in patients diagnosed before 30 years of age.

Announced in a statement from TransMedics Group Inc. on September 7, premarket approval to the OCS Heart System could allow for broader utilization of donor hearts for transplantation in the US.

Editorial advisory board member Dr. Paul Thompson reflects on how advances in diabetes management have impacted cardiovascular medicine and why staying abreast of these advances is essential to being a cardiologist in 2021.

Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.

The mortality rate has not declined since the 1970s.

Intensive systolic blood pressure control led to a large absolute difference in death and HF among patients with abnormal biomarker levels of hscTnT and NTproBNP.

Wellness trainers educate patients on how to begin exercise programs and then track progression and results of patients to aid in rehabilitation process.

Results of a post hoc analysis of the TWILIGHT trial provide insight into the effects of ticagrelor monotherapy compared to dual therapy with aspirin in patients with concomitant CKD and diabetes.

Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Gregory Weiss, MD, provides an overview of the updated cardiovascular disease prevention guidelines from the European Society of Cardiology, which were released at ESC Congress 2021.

Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

The Amulet IDE Trial is the first trial to offer a head-to-head comparison of the Amplatzer Amulet occluder from Abbot against the Watchman device from Boston Scientific for left atrial appendage occlusion.

A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Gregory Weiss, MD, reviews and offers perspective on a study presented at ESC Congress 2021 examining the association between influenza vaccines and improved outcomes in patients with cardiovascular disease.